Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 14/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23256879 | 0.89 | P2RY1 (0.50) | P2RY1DYRK1AKMT2AGSK3B | |
| SCHEMBL21568207 | 0.88 | DYRK1A (0.47) | P2RY1DYRK1ANPC1RAB9AMEN1 | |
| SCHEMBL21568098 | 0.87 | DYRK1A (0.46) | P2RY1DYRK1AKMT2AGSK3B | |
| SCHEMBL21568277 | 0.86 | DYRK1A (0.44) | P2RY1DYRK1AMEN1KMT2AGSK3B | |
| SCHEMBL23256633 | 0.85 | P2RY1 (0.45) | P2RY1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL23256634 | 0.85 | P2RY1 (0.42) | P2RY1DYRK1AGSK3B | |
| SCHEMBL21568065 | 0.84 | DYRK1A (0.57) | P2RY1DYRK1ANPC1RAB9AMEN1 | |
| SCHEMBL21568286 | 0.83 | P2RY1 (0.45) | P2RY1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL23256876 | 0.82 | MAPT (0.53) | P2RY1DYRK1ANPC1RAB9AMEN1 | |
| SCHEMBL23256878 | 0.81 | CXCR2 (0.41) | P2RY1DYRK1ANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2021-04-22 | — | — | US | disclosed |
| WO-2019217509-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | P2RY1 1428/4885DYRK1A 4664/4885NPC1 424/4885 |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | VHL, TP53, NUDT1 | P2RY1 1312/4885DYRK1A 4618/4885NPC1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.